John Skylar Westerdahl

John Skylar Westerdahl

Auto-generated profile, based on publicly available information

John Skylar Westerdahl

Department of Dermatology University of Utah Salt Lake City Utah USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
JWJ. S. Westerdahl
J. S. Westerdahl
KNK. B. Nusbaum
K. B. Nusbaum
CCC. G. Chung
C. G. Chung
BKB. H. Kaffenberger
B. H. Kaffenberger
AOA. G. Ortega-Loayza
A. G. Ortega-Loayza
/Summary Pyoderma gangrenosum (PG) is a rare neutrophilic skin disease characterized by painful skin ulcerations with violaceous borders. Although the mainstay of PG treatment is based on the use of immunosuppressive agents, there is no gold-standard treatment algorithm in refractory cases. Within the last decade there has been an increasing number of case reports on the use of ustekinumab for the treatment of PG. Herein we present a clinical summary of seven patients with PG successfully treated with ustekinumab in combination with the 18 other cases currently in the literature. These cases suggest ustekinumab should be used as an adjuvant therapy for refractory cases and a possible steroid sparing option. Prospective clinical studies are ultimately needed to further characterize the efficacy and safety of ustekinumab in PG.

25 March 2022 in Case Reports in Dermatological Medicine
Verified
Journal Article
Open access
PDF file
AWA. Walker
A. Walker
JWJ. S. Westerdahl
J. S. Westerdahl
JZJ. Zussman
J. Zussman
JMJ. Mathis
J. Mathis
Interstitial granulomatous drug reaction (IGDR) is a distinct inflammatory process that often presents as annular, violaceous plaques distributed on the extremities, proximal trunk, and intertriginous areas. The list of drugs implicated for inciting IGDR is growing, but most prominently includes ACE inhibitors, antihistamines, beta-blockers, antidepressants, and anticonvulsants. Ustekinumab is a human monoclonal antibody that targets inflammatory cytokines IL-12 and IL-23 and has been have shown to be effective in treating IGDR. However, we present a case that suggests ustekinumab can also act as an inciting agent for IGDR.

31 December 2024 in JEADV Clinical Practice
Verified
Journal Article
Open access
NUNicole Ufkes
Nicole Ufkes
ZHZachary Hopkins
Zachary Hopkins
JWJohn Skylar Westerdahl
John Skylar Westerdahl
SFScott R. Florell
Scott R. Florell
Background: Patients with diabetes have an increased risk of certain dermatophytoses. However, less is known about dermatophyte infections in pre‐diabetic patients, or how A1c impacts risk.Objectives: Assess the relationship between recent (< 1 year) HgbA1c status and odds of cutaneous dermatophyte infection.Methods: Case–control study of patients seen at the University of Utah Dermatology Department between January 1, 2015 and December 21, 2022. Tinea cases were identified by ICD‐10 codes and required the diagnosis be made by a dermatologist. Controls included patients seen in the dermatology department but who had no known diagnosis (past or current) of dermatophyte infection and were seen in a context where tinea could have been identified (i.e., no surgical visits, suture removals, spot checks, and cosmetic visits) and did not have a potentially confounding condition (inflammatory rashes). The primary exposure examined was averaged HgbA1c 1 year before index visit. Secondary exposures included HgbA1c 3 months, 3–6 months, and 6–12 months before visit as well as 3 months after the visit. Sensitivity analysis was performed using categorised Hgb A1c and historical diagnosis of diabetes.Results: There was a 1.16‐fold increase in the odds of tinea per point increase in averaged pre‐visit A1c (odds ratio [OR] 1.16; confidence interval [CI] 1.11–1.22). The odds of tinea for a given HgbA1c were higher for cutaneous tinea as compared to onychomycosis and tinea capitis. The odds of tinea were attenuated when adjusting for age and sex but remained significant (OR = 1.09; CI 1.03–1.15).Conclusions: There was an association between averaged HgbA1c over the year before a visit and odds of tinea infection. This association was similar for individual A1c periods and was more pronounced for tinea infections outside of onychomycosis and tinea capitis. These data may support HgbA1c screening in patients with new dermatophytoses, or conversely may increase the suspicion of cutaneous dermatophytosis if HgbA1c is elevated.

1 June 2026 in Annals of Translational Medicine
Verified
Journal Article
Open access
JWJ. Skylar Westerdahl
J. Skylar Westerdahl
RSRichard D. Sontheimer
Richard D. Sontheimer
Chronic eczematous skin disorders that first appear in later life are poorly characterized, partly because existing terminology is inconsistent and often conflates morphologic descriptors with specific diagnoses. This review introduces chronic eczematous eruptions of aging (CEEsA) as an umbrella term, summarizes current knowledge on its epidemiology, etiologies, and clinical presentation, outlines best practices in management, and highlights gaps requiring further investigation. CEEsA frequently present as ill defined, intensely pruritic eruptions on the trunk and extensor limbs, are often refractory to standard topical therapies, and may be precipitated by calcium channel blockers or thiazide diuretics. A structured diagnostic algorithm—incorporating exclusion of mimickers (e.g., tinea pedis-linked auto-eczematization, scabies, contact dermatitis, cutaneous T-cell lymphoma), lesional biopsy, patch testing, and strategic drug withdrawal—is essential before escalating to systemic therapy. This approach helps avoid unnecessary treatment or other etiologies with different management. Although traditional broad spectrum immunosuppressants carry age related safety concerns, emerging targeted agents that dampen type 2 cytokine signaling (dupilumab, tralokinumab) or Janus kinase pathways (upadacitinib) show promising efficacy and tolerability in small case series of CEEsA, including idiopathic forms. Recognizing CEEsA as a distinct clinical construct should streamline nomenclature, sensitize clinicians to reversible drug triggers, and catalyze research into pathophysiology-specific, age appropriate treatments for this under studied geriatric dermatology domain.